Table 2A. Univariate modelling for PFS in KRas WT patients.

	HR (95% CI)	P-value
Age: median	1.32 (0.58–2.99)	0.5
Gender	0.84 (0.35–2.05)	0.71
Race	1.56 (0.66–3.71)	0.36
White vs minorities (Black, Hispanic, Other)
Colon vs rectum	0.89 (0.41–2.00)	0.79
Stage IV vs recurrence	1.51 (0.69–3.30)	0.3
Mets sites (1 vs 2 or more)	1.66 (0.73–3.78)	0.22
Diff (well vs mod/poor)	0.80 (0.23–2.75)	0.73
Chemo lines (1 vs 2 or more)	1.54 (0.36–6.65)	0.57
CEA at Dx St IV (dichot at median 26)	0.58 (0.26–1.28)	0.17
Telomere length	0.42 (0.14–0.79)	0.012

Abbreviations: CEA at Dx St IV (dichot at median 26)=carcinoembryonic antigen at diagnosis of stage IV disease, and dichotomised at median of 26; CI=confidence interval; diff=differentiation; HR=hazard ratio; Mets=metastases; mod=moderate; PFS=progression-free survival; WT=wild type.

The table depicts results of univariate modelling of all important clinical characteristics that could impact the clinical outcome of patients when treated with anti-EGFR therapy. Each row depicts the characteristic, followed by the HR and the associated P-value for each variable.